WAVE Life Sciences Receives Buy Rating and USD 16 Price Target from Citigroup

Citigroup has initiated coverage on WAVE Life Sciences (WVE) with a "Buy" rating and a price target of $16.00. The initiation reflects Citigroup's confidence in the company's future prospects and could influence investor sentiment. Based on analyst estimates, the average target price for WVE is $20.33, implying an upside of 163.73% from the current price. The estimated GF Value for WVE in one year is $3.38, suggesting a downside of 56.16% from the current price.

Citigroup has initiated coverage on WAVE Life Sciences (WVE) with a "Buy" rating and a price target of $16.00. This move by Citigroup reflects their confidence in the company's future prospects and could significantly influence investor sentiment. According to Investing.com, the analyst consensus remains strongly bullish, with price targets ranging from $9 to $36, suggesting substantial upside potential from current levels [2].

Citigroup highlighted several upcoming data releases that could impact the stock, including multi-dose data for WVE-006, an RNA editing treatment for Alpha-1 Antitrypsin Deficiency (AATD), expected in the third quarter of 2025. The firm noted potential for this treatment to elevate total AAT protein levels "meaningfully above the 11uM protective threshold" [2].

The research note also mentioned WVE-007, a GalNAc-siRNA treatment for obesity, with initial Phase 1/2 data anticipated in the second half of 2025. This data will help characterize the safety profile and weight loss efficacy of this novel mechanism [2].

WAVE Life Sciences is advancing additional pipeline candidates, including WVE-N531 for Duchenne muscular dystrophy with an NDA filing targeted for 2026, and WVE-003 for Huntington’s disease, with a potentially registrational Phase 2/3 trial expected to begin in the second half of 2025 [2].

The company recently presented preclinical data at the American Diabetes Association’s 85th Annual Scientific Sessions, showing that its candidate, WVE-007, led to significant weight loss in diet-induced obese mice. This weight loss was achieved primarily through fat mass reduction while preserving muscle mass, a key differentiator from other treatments [2].

The estimated average target price for WVE is $20.33, implying an upside of 163.73% from the current price. The estimated GF Value for WVE in one year is $3.38, suggesting a downside of 56.16% from the current price [2].

References:
[1] https://www.marketscreener.com/quote/stock/WAVE-LIFE-SCIENCES-LTD-24885566/news/Citigroup-Initiates-Wave-Life-Sciences-at-Buy-With-16-Price-Target-50525548/
[2] https://www.investing.com/news/analyst-ratings/citi-initiates-coverage-on-wave-life-sciences-stock-with-buy-rating-93CH-4137317